( NYSE:GSK,NYSE:PFE )

News from viiv healthcare A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 16, 2016, 08:55 ET ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment

ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir...


Jul 18, 2016, 06:15 ET ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV

ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior...


Feb 24, 2016, 12:12 ET ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented...


Feb 23, 2016, 14:49 ET ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment

32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen...


Jan 19, 2016, 08:30 ET ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists

 ViiV Healthcare and the Los Angeles Department of Health Services (LA DHS) today announced the launch of the ViiV Healthcare/LA DHS HIV Public...


Jan 07, 2016, 08:31 ET ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration...


Nov 03, 2015, 08:24 ET ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb...


Sep 23, 2015, 05:27 ET New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression

ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and...


May 26, 2015, 09:00 ET ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV

ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an...


May 06, 2015, 04:51 ET ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine   ViiV Healthcare today announced the start of a...


Feb 04, 2015, 09:30 ET ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men

 ViiV Healthcare today announced the launch of a four-year, $10 million initial investment to fuel a concerted community response to the HIV...


Aug 25, 2014, 19:32 ET ViiV Healthcare recibe aprobación de la FDA para Triumeq® (abacavir, dolutegravir y lamivudine), una nueva régimen de tableta única para el tratamiento de la infección por VIH-1

El material multimedia relacionado con el aviso a continuación ya está disponible. El material incluye: material complementario en video,...


Aug 22, 2014, 15:46 ET ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and...


Apr 01, 2014, 15:01 ET Medicines Patent Pool e ViiV Healthcare assinam licença para o mais recente medicamento contra o HIV que recebeu aprovação regulamentar

A Medicines Patent Pool (MPP) e a ViiV Healthcare anunciaram uma nova colaboração em medicamentos para o HIV hoje, assinando dois acordos...


Apr 01, 2014, 14:30 ET El Medicines Patent Pool y ViiV Healthcare firman una licencia para el medicamento contra el VIH de aprobación regulatoria más reciente

El Medicines Patent Pool (MPP) y ViiV Healthcare anunciaron hoy un nuevo acuerdo de colaboración sobre medicamentos para el VIH, firmando dos...


Apr 01, 2014, 14:30 ET ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name...


Mar 19, 2014, 09:45 ET ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence

 ViiV Healthcare today issued a new request for letters of interest (LOIs) for the sixth round of its Positive Action Southern Initiative...


Jan 21, 2014, 06:52 ET ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

 ViiV Healthcare today announced that the European Commission has approved Tivicay™ (dolutegravir), an integrase inhibitor, for use...